HFA Premium Access

Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: Insights from the GALACTIC-HF trial.

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Congress Presentation

About the speaker

Professor John J V McMurray

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
127 presentations
19 followers

13 more presentations in this session

Omecamtiv Mecarbil in Patients with Severe Heart Failure: An Analysis from Global Approach to Lowering Adverse Cardiac Outcomes through Improving Contractility in Heart Failure (GALACTIC-HF)

Speaker: Professor G. Felker (Durham, US)

Thumbnail

Association of Baseline Cardiac Biomarkers on Clinical Outcomes and Vericiguat Treatment Effect in Heart Failure with Reduced Ejection Fraction: Insights from the VICTORIA Trial

Speaker: Associate Professor C. DeFilippi (Baltimore, US)

Thumbnail

Efficacy and Safety of Antithrombotic Strategies in Patients With Atrial Fibrillation and Recent ACS or PCI With and Without A History of Heart Failure: Insights From the AUGUSTUS Trial

Speaker: Doctor M. Fudim (Durham, US)

Thumbnail

Nurse Intervention for Less Chronic Heart Failure Study

Speaker: Professor S. Stewart (Sydney, AU)

Thumbnail

Telemedical Interventional Management in Heart Failure

Speaker: Professor F. Koehler (Berlin, DE)

Thumbnail

Access the full session

Clinical Trial Updates

Speakers: Professor J. McMurray, Professor G. Felker, Associate Professor C. DeFilippi, Doctor M. Fudim, Professor S. Stewart...
Thumbnail

About the event

Image

Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations